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Abstract: The objective of this study was to evaluate the acute response of Sencil
TM, a  
fiber-optic sensor, in point accuracy for glucose monitoring in vivo on healthy dogs under 
anesthesia.  A total of four dogs with clinically normal glycemia were implanted with one 
sensor each in the chest region to measure the interstitial glucose concentration during the 
ovariohysterectomy procedure. The data was acquired every 10 seconds after initiation, and 
was compared to the concentration of venous plasma glucose sampled during the surgery 
procedures  for  accuracy  of  agreement  analysis.  In  the  four  trials  with  a  range  
of 71–297 mg/dL plasma glucose, the collected 21 pairs of ISF readings from the Sencil
TM 
and  the  plasma  reference  showed  superior  dispersion  of  residue  values  than  the 
conventional system, and a linear correlation (the Pearson correlation coefficient is 0.9288 
and the y-intercept is 14.22 mg/dL). The MAD (17.6 mg/dL) and RMAD (16.16%) of 
Sencil
TM measurements were in the comparable  range of the conventional system. The 
Clarke error grid analysis indicated that 100% of the paired points were in the clinically 
acceptable zone A (61.9%) and B (38.1%). 
Keywords:  in vivo glucose monitoring; fiber-optic sensor; point accuracy; Clarke error 
grid analysis; calibration 
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1. Introduction  
The  ultimate  goal  of  glucose  sensing  development  is  to  fulfill  the  requirements  of  a  complete 
artificial  pancreas,  with  a  continuous  in  vivo  monitoring  for  fine-tuning  an  insulin  pump  by  
closed-loop control [1,2]. Such a treatment could dramatically reduce mortality and complications from 
the chronic metabolic fluctuations in either hyperglycemia or hypoglycemia, and alleviate the burden of 
care delivery cost [3,4]. Above all, this hypothetical system could significantly improve the living 
quality of millions of diabetes sufferers worldwide to resemble the life of healthy individuals. In the 
current clinical environment, insulin delivery technology (insulin formulation and pump designs) is 
well  developed,  however  glucose  sensors  for  continuous  in  vivo  monitoring  remain  problematic, 
especially with regards to the kinetic response in the hypoglycemia region [5,6]. Presently, intermittent 
self-monitoring  of  blood  glucose  (SMBG)  is  the  clinical  method  of  choice,  which  provides  point 
accuracy  and  has  been  verified  by  Clarke  error  grid  analysis  (conventional  devices  have  95–99% 
accuracy)  [7].  However,  an  ideal  glucose  sensor  for  an  artificial  pancreas  should  provide  clinical 
accuracy not only in the aspect of absolute glucose value at a specific time (point accuracy) but also the 
rate and direction of concentration change (rate accuracy) [7]. It has been noted that physiological 
insulin secretion from β-cells (insulin secretion portion in the pancreas) has a biphasic response toward 
a step change of glucose, which can be simulated by a close-loop feedback controlled insulin pump 
with a PID controller [6,8,9]. The PID controller will be adjusted by three coefficients:  proportional to 
the  error  (measured  glucose  concentration  minus  target  concentration);  the  area  under  the  curve 
(integral)  of  the  error;  rate  of  change  (derivative)  of  the  error.  The  point  accuracy  of  the  signal-
feedback sensor has the dominant influence on the “P” component (control gain); on the other hand, 
the “I” (direction of change) and “D” (rate of change) components will be counted on a sensor with 
reliable rate accuracy.    
Sencils
TM are a family of fiber-optic sensors, capable of providing analyte monitoring in vivo for 
several weeks [10,11]. The key element is a chronically implantable and human hair-like optical fiber 
(Figure 1a)  that  permits  reliable  spectroscopic  measurement  of  chemical  reactions  from  the 
subcutaneous end of the fiber (Figure 1b). The technology can benefit not only clinical applications, 
but also veterinary medicine and basic molecular biology research. Preliminary animal implantation 
studies have demonstrated good chronic biocompatibility and durability [11]. Its first application was 
to  measure  glucose  based  on  changes  in  fluorescence  resonance  energy  transfer  (FRET)  between 
fluorophores bound to betacyclodextrin and concanavalin A (Con A) in a polyethylene glycol (PEG) 
matrix attached to the implanted end of the fiber (Figure 1c). In vitro experiments demonstrated a rapid 
and linear relationship between the ratio of the two fluorescent emissions and concentration of glucose 
in saline for the physiological range of concentrations (0–500 mg/dL) over seven weeks [10]. The 
preliminary results confirm that applying ratio as the concentration index makes the reversible assay 
insensitive to variability of the photonic coupling or deterioration of the sensing materials over time. It 
could allow the device possess an internal standard without the necessity to calibrate daily based on the 
SMBG reading.  
Like most of the minimal and noninvasive designs for continuously in vivo glucose monitoring [12-15], 
Sencil
TM  measures  glucose  in  the  interstitial  fluid  (ISF)  compartment  of  skin  to  estimate  plasma 
glucose. Although the concentration of the plasma glucose is the clinical index in identifying and Sensors 2010, 10                                       
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managing  diabetes,  the  ISF  glucose  concentration  has  a  closer  correlation  to  the  development  of 
complications on the peripheral tissues through the regional cell-level activities [16]. The ISF glucose 
and plasma glucose are expected to have different steady-state concentrations and kinetic responses 
under conditions with all the physiological barriers [17,18], but the detection is the main objective due 
to its ease of use and safe accessibility. The estimation of plasma glucose from ISF glucose introduces 
discrepancy from the sensor detection and time delay of the concentration gradient between the blood 
pool and ISF through the capillary vessel wall. The concentration gradient between ISF and plasma can 
be  approximated  by  the  two-compartment  model  [17,19,20].  The  main  challenge  of  the  detection 
accuracy is on the design to minimize the sensor delay and the establishment of a valid and efficient  
in vivo calibration [12,13,16,20,21].   
 
Figure 1. Illustration of the Sencil
TM system for glucose sensing. (a) Similarity of shape 
and size between Sencil
TM and human hair with attached follicle (white bar = 100 µm).  
(b) Sensor components and relationships to tissue in vivo. (c) Changes in FRET between 
fluorophores covalently immobilized on the flexible PEG matrix depend on changes in the 
distance between them, which in turn depends on the competitive natural affinity between 
Con  A  and  various  saccharides  such  as  betacyclodextrin  and  glucose.  The  figure  is 
modified with permission from [10], published by Biosensors Bioelectronics, 2008.  
 
 
 
The aim of this paper was to study the acute response of Sencil
TM for glucose detection in a clinical 
environment and address the follow questions: (1) how long does the sensor settled in tissue after 
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implantation for short-term applications, and (2) how accurate is the measurement from acute response 
under in vitro calibration, and (3) how accurate is the acute response to estimate plasma glucose from 
the ISF detection? The information is crucial to establish foundation for further in vivo testing in 
elaborating the sensor accuracy of full working range through glucose clamp experiments, and chronic 
in vivo performance. 
2. Experimental Section  
2.1. Canine Subjects 
Four clinical healthy dogs scheduled for ovariohysterectomy were selected for the study. All dogs 
had a record of normal glycemia when admitted. Physical examination of each dog was performed by a 
board-certificated  veterinary  surgeon  or  veterinary  resident  to  confirm  the  subject’s  health.  The 
hematological  profile  (WBC,  RBC,  Hb.,  Hct.,  MCV,  MCH,  MCHC,  Thromob.,  Parasite)  and 
bloodchemistry profile (AST/STOG, ALT/SGPT, LDH, CK, Alk. P’tase, Glucose, BUN, Creatinine, T. 
protein, Albumin, Calcium, Phosphorous) were verified within normal limits by Hitachi 7050 prior the 
induction of anesthesia. The study protocol was approved by the National Chung-Hsing University 
Institutional  Animal  Care  and  Use  Committee  (IACUC  Approval  No.:  98-19),  and  consent  was 
obtained from owners of all participating subjects.  
2.2. Anesthesia 
Anesthesia  was  induced  with  intravenous  administration  of  medetomidin  125  mcg/m
2  and  
propofol 2 mg/kg. Dogs were endotracheally intubated and anesthesia was maintained with inhalation 
of isoflurane in oxygen (1% to 2.5% isoflurane). The isoflurane vaporizer was adjusted as necessary to 
maintain an appropriate anesthetic status. All dogs received an IV infusion of lactated Ringer’s solution 
(Dog #1-3) or dextrose-lactated Ringer’s solution (Dog #4) in the flow rate of 10 mL/kg/h, throughout 
the anesthesia periods.  
Figure 2.  Illustration of the relative spacial positions for implantation, blood sampling and 
IV infusion on each subject (a). Arrangement of devices around the operation table (b). 
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2.3. Sensor Placement and Spacial Arrangements 
The relative spacial positions of implantation site, blood sampling sites, IV injection site are shown 
in Figure 2. A Vasofix catheter was placed on the right foreleg for following blood samplings. The IV 
infusion was flowed through the catheter on the left foreleg. The Sencil
TM was implanted on the chest 
about 10 cm away from the blood sampling site. The arrangement can avoid the accidental removal of 
the sensor probe from the skin, due to the forced movement of limb during sampling or a relatively 
more dramatic involuntary movement from leg (or another body part) under anesthesia.  
After induction of anesthesia, the dogs were managed to supine position on the surgery table with 
restraints on the end of their four limbs. Hair in the chest and abdomen regions was shaved and those 
areas were cleaned with scrubbing chlorhexidine and alcohol. The detection end of the optical fiber 
(with hydrogel attached) was introduced percutaneously by a disposable sterilized gauge 23 needle in a 
shallow angle along the surface of the skin. The needle was pulled out off skin when the sensor probe 
was placed about 1–2 cm deep. The external end of the optical fiber was connected to the portable 
spectrophotometer  system  [10]  through  a  SMA  type  connector.  Dermabound  was  applied  on  the 
implantation site (for all subjects), and portion of the optical fiber extended out of skin was adhered on 
the skin surface with elastic adhesive tape (Dog #1-3 only, not on Dog #4) to secure the implantation. 
All the shank of the optical fiber, which was protruding out of the skin, was covered with aluminum 
foil to shield the detection from the ambient light.    
2.4. In Vitro Sensor Calibration  
Six sensors were made in the same batch, and four of them were applied in the study during a  
time-span of five months. Each of them was stored in a dry sterilized pouch under the conditions 
specified in [10] before the study. The calibration curve was obtained from the sensor in 0, 100, 200, 
300, 400, 500 mg/dL glucose salines (pH 7.4 phosphate buffer) one day prior to the implantation. The 
detected glucose concentration was calculated from the ratio of the two absolute value of fluorescence 
at their maximal emission wavelength (indicated by the arrows in Figure 3a). The conversion was 
based on least square linear fitting of the results. The characterization of the sensor for Dog #1 study is 
shown  in  Figure  3b,  and  the  other  sensors  had  similar  fitting  slopes  and  y-intercepts  with  the 
differences were less than 5%. The standard deviation of the calibration value in each corresponding 
glucose concentration is shown in Figure 3b. 
2.5. Initiation and Processing of Monitoring  
During in vivo monitoring, the absolute emissions (unit photon counts) at 525 nm and 570 nm (the 
maximal emission wavelength of the two fluorophores) were acquired every 10 seconds as two analog 
signals.  Those  analog  signals  were  digitized  and  processed  on  a  laptop  computer  installed  with 
OOIBase 32 software through a USB connection to calculate the emission ratio (525 nm/570 nm) at 
each acquisition (data point). The data point which was recorded at the time of venous blood sampling 
was applied to be compared with the plasma reading. Sensors 2010, 10                                       
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Figure  3.  Sensor  calibration  from  the  linear  fitting  result  of  in  vitro  measurements.  
(a) Absolute emissions at 525 nm and 570 nm (arrows) were applied to calculate the ratio 
for indicating glucose concentration. (b) Linear correlation between the emission ratios and 
the corresponding glucose concentrations. The standard deviations (from the six sensors 
manufactured  in  the  same  batch)  of  the  calibration  values  at  corresponding  glucose 
concentrations are shown as green error bars. 
 
 
After implantation, both maximal emissions at corresponding wavelengths were observed to have a 
significant 2–3 fold decline in the four separate studies. This could be explained by two optical events: 
firstly, the ambient light contributed partially in the detected signal before implantation. It had a board 
emission spectrum from 450 nm to 800 nm, and its intensity at 525 nm was about three times the 
intensity at 570 nm. Secondly, more excitation was backscattered at the interface of hydrogel with the 
surrounding  air  before  implantation.  The  reflection  of  normal  incidence  on  the  interface  can  be 
calculated from equation 1 to demonstrate a 10-fold increase in air (n = 1.0003) than in a water rich 
environment (n = 1.33, such as in cell clusters) when the refractive index of hydrogel is assumed to  
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be 1.45. The dramatic change in emission intensity can be applied as index to check if the device falls 
out of skin during experiment.  
2 ) (
hydrogel
hydrogel
n n
n n
R
+
−
=           (1) 
Figure  4  demonstrates  the  relatively  mild  transition  (~30%)  of  emission  ratio  before  and  after 
implantation from study one while the other three studies shared the similar trends. The whole process 
of settling periods in the four studies were consistently in the range of 3–6 minutes, which is similar to 
the temporal  response  of Sencil
TM to a step change of glucose from the in vitro studies [10] and 
provides  the  evidence  to  support  the  hypothesis  that  diffusion  of  bio-fluid  into  the  matrix  could 
gradually  reduce  the  refractive index of hydrogel, and account for the change. For further in vivo 
studies, all monitoring should be initiated at approximately 10 minutes after the implantation to avoid 
the interference from the transition process based on the present observations. 
Figure 4. Fluorescence emission ratio change trend before and after implantation. 
 
3. Results and Discussion  
3.1. Canine Subjects 
Four dogs, three mixed-breed and one Golden Retriever were included in this research. The mean 
body weight was 20 kg (from 13 to 32 kg). All subjects underwent standard ovariohysterectomy in the 
abdomen region and anesthesia for 125 to 186 minutes. The venous blood samples were drawn (1 mL) 
from the foreleg (specified in Figure 2) in the interval of 13 to 56 minutes without interfering with the 
progress of the surgery. A total of 21 pairs of ISF readings from Sencil
TM and plasma glucose reference 
from the Hitachi 7050 instument were collected for analysis.  
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Figure  5.  Profiles  of  the  ISF  reading  from  Sencil
TM  and  plasma  reference  from  
Hitachi 7050. (a) case study #1 (b) case study #2 (c) case study #3 (d) case study #4. 
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Figure 5. Cont. 
 
3.2. Canine Studys #1-3 
The studies of Dogs #1-3 had similar experimental conditions, including the glucose-free infusions, 
which started 5–15 minutes prior the initiation of ISF glucose monitoring by Sencil
TM. The detected 
ISF  glucose  of  Dogs  #1-2  fluctuated  mostly  in  the  normal  canine  glycemia  range  (plasma  
glucose 65–110 mg/dL) with less than 10% of detections below or above the range (Figures 5a and 5b). 
The  corresponding  mean  (standard  deviation)  values  of  the  two  trials  were  82.9065  (±9.5001)  
and 83.6616 (±9.2934) mg/dL. However, the ISF glucose level of dog #3 appeared to be maintained at 
the lower limit of the normal glycemia during the first 2/3 of the anesthesia period (Figure 5c). Its 
mean (standard deviation) value was 74.0334 (±12.5593), and it showed the largest discrepancy (the 
mean absolute difference, MAD, was 19.75 mg/dL calculated by Equation 2, or the relative mean 
absolute difference, RMAD, calculated by Equation 3) between the ISF reading and plasma reference 
in the three trials (the corresponding MAD and RMAD values of trial 1 and 2 were 10.39 mg/dL, 
9.75% and 7.01 mg/dL, 6.64%).  
) ( ISF Plasma mean MAD − =            (2) 
% 100 ) ( ×
−
=
Plasma
ISF Plasma
mean RMAD         (3) 
3.3. Canine Study #4 
Case  study  #4  chose  a  glucose-included  infusion  to  induce  hyperglycemia  during  monitoring  
(Figure 4d). The ISF glucose level climbed up all the way from normal glycemia range and eventually 
reached a plateau around 300 mg/dL detected by Sencil
TM. The anchorage of Sencil
TM was enhanced by 
Dermabond only in this study, without the application of elastic adhesive tape as the other three trials. 
The probe fell out three times during the monitoring procedure due to involuntary movements of the 
subject. A 2–3 fold emission intensity was observed during those periods, however the corresponding 
emission ratio was only slightly elevated (<10%). The Vasofix catheter for blood sampling formed a 
blood clot that could not be fixed with heparin injection, so the last venous blood sample was collected 
(d) Sensors 2010, 10                                       
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from the rear leg of the subject. A plasma reading at 637 mg/dL was collected 26 minutes before the 
last sampling with the venous blood drawn from the IV-infused limb, and was not included in the 
following analysis. The MAD and RMAD values of this case were 41.25 mg/dL, 18.49%. 
3.4. Accuracy of Agreement between Sencil Detections and Plasma Reference for Clinical Application  
The  accuracy  of  agreement  between  Sencil
TM  measurements  and  plasma  reference  for  in  vivo 
glucose  monitoring  was  assessed  by  the  method  of  residues,  linear  correlation,  mean  absolute 
difference, and Clarke error grid analysis. In the four trials with a range of 71–297 mg/dL plasma 
glucose,  the  collected  21  pairs  of  ISF  reading  from  Sencil
TM  and  plasma  glucose  reference  from  
Hitachi  7050  showed  that  Sencil
TM  slightly  overestimated  the  plasma  reference  value,  which  was 
indicated  by  the  positive  mean  of  difference  (mean  =  17.6  mg/dL).  The  MAD  (17.6  mg/dL)  and 
RMAD (16.16%) of Sencil
TM measurements were in the similar range of the conventional Medtronic 
continuous  in  vivo  monitoring  system  [26].  However,  the  dispersion  of  values  (expressed  as  
mean ± 2 std) around the mean difference was lower for Sencil
TM (45 mg/dL, shown in Figure 6a) than 
with  the  conventional  system  (84 mg/dL).  A  linear  correlation  (the  Pearson  correlation  coefficient  
is 0.9288 and the y-intercept is 14.22 mg/dL) between ISF reading and plasma reference is shown in 
Figure 6b. The Clarke error grid analysis indicated that 100% of the points are in the clinical acceptable 
zone A (61.9%) and B (38.1%) as shown in Figure 6c. The results of accuracy agreement analysis 
implied the potential of the sensor for clinical application from limited number of trials. However, a 
relative larger discrepancy was observed when the ISF glucose had more significant shift such as case 
studies #3 and 4, which could be resolved in the following directions: 
 
Figure  6.  Accuracy  of  agreement  between  Sencil  reading  and  plasma  reference:  
(a) Bland-Altman method analysis; (b) least square linear fitting result; (c) Clarke error  
grid analysis.  
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Figure 6. Cont. 
 
 
 
First of all, the study did not correct for the diffusion lag which results from the concentration 
gradient  between  the  blood  pool  and  the  ISF  compartment.  Typically,  ISF  glucose  falls  ahead  of 
plasma glucose when glycemia declines due to the regional uptake (triggered by endogenous insulin), 
and lags behind plasma glucose when glycemia increases. The time constant of the two phases can be 
derived  from  the  two  compartment  model  through  a  series  of  glucose  clamp  studies,  endogenous 
hypoinsulinemic tests and endogenous hyperinsulinemic tests [17,19,20]. Secondly, the ISF glucose is 
calculated from the absolute emission intensity at 525 nm and 570 nm (Figure 3a), the theoretical 
emission  maximal  wavelengths  of  the  two  fluorophores  (Qdot  and  FITC)  in  the  sensing  matrix. 
However, the peak amplitudes of each are influenced by the skirts due to overlap of the two emissions 
spectra. The problem is exacerbated for high glucose concentrations (>300 mg/dL) in which Qdot 
(b) 
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fluorescence is less quenched by FRET and the emission peak of TRITC is completely obscured by the 
Qdot emission. Hypothetically, estimating the area-under-the-curve attributable to each fluorophore 
and filtered by numerical signal processing tools, such as independent component analysis could be the 
potential remedy for this problem. Thirdly, the implanted component of the sensor could induce a 
foreign body reaction that changes the local concentration of the analyte or that blocks diffusion of the 
analyte  to  the  transduction  point  for  chronic  application  [23-25].  Immediately  upon  contact  with 
extracellular fluid (especially blood), proteins and other chemicals will adsorb onto and diffuse into the 
sensor,  which  may  block  protective  or  analyte-selective  membrane;  and  a  fibrous  capsule  will  be 
formed progressively during post-implant days 4–12, potentially blocking diffusion of the analyte.  The 
capsule  may  have  low  or  fluctuating  concentrations  of  oxygen,  glucose  and  other  metabolites 
depending on the ratio of metabolic activity of the capsular cells to the circulation provided by the 
interrupted  and  reforming  capillary  bed.  It  might  result  in  detection  drift.  Although  the  Sencil
TM 
implant has been verified to form a stable interface with the surrounding tissue [11], the effect of the 
relatively thin encapsulation should be tested in a chronic monitoring study. In this study, we observed 
the acute response on glucose sensing without a stable device/issue interface. The condition is similar 
to all of the present FDA-approved continuous monitoring systems (Guardian
® system and Paradigm
® 
system of Medtronic, and Seven Plus system of Dexcom start measurement at 2 hours after insertion; 
Freestyle Navigator
® of Abbott begins at 10 hour). They all need several in vivo calibrations against 
plasma glucose at specific timeframes in their lifetimes (3–7 days) to adjust the tissue responses. The 
preliminary result of this study suggested that the acute response of the fiber-optic sensor possesses 
reasonable  accuracy  for  clinical  application  without  in  vivo  calibration.  According  to  the  recent 
literature reports [24,25] on the tissue response to needle type enzymatic continuous glucose sensors 
(general design scheme of all the marketed systems mentioned above), the detection was not apparently 
affected in the early phase response to the trauma.  It was the fibrous capsule formed in the end stage of 
foreign body reaction caused the most disturbances in glucose sensing, and eventually the function loss 
of the device. We have demonstrated that the small size and biocompatibility of the fiber-optic sensor 
formed relatively much thinner fibrous capsule than the needle type enzymatic continuous glucose 
sensors [11,24], and intend to verify that the Sencil
TM will have longer lifetime due to the relatively 
mild foreign body reaction in the future studies. 
4. Conclusions  
The present acute response study demonstrates the close correlation between ISF glucose readings 
from Sencil
TM and plasma glucose reference values over an approximately two hours of monitoring 
after calibration based on in vitro glucose saline readings. Further point accuracy analysis over the 
potential working range, rate accuracy analysis and chronic monitoring experiment will identify the 
feasibility of Sencil
TM for continuous glucose monitoring in vivo, or ultimately as a the closed-loop 
feedback input for an artificial pancreas.  
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